The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which

The COVID-19 pandemic has reshaped global health strategies, pushing preventive measures to the forefront of public attention. Now, there is a renewed focus on fortifying defenses against future viral threats and ways to improve hospitalization rates. Here, we will explore the latest advancements in post-pandemic prevention strategies and the broader landscape of public health.

Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign